ILMN Illumina Inc.

INVESTOR ALERT: Investigation of Illumina Inc. Announced by Law Offices of Howard G. Smith

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Illumina Inc. (“Illumina”) or the “Company”) (NASDAQ: ILMN) concerning the Company and its officers’ possible violations of federal securities laws.

On October 10, 2016 Illumina issued a press release announcing disappointing financial results for the third quarter of fiscal year 2016. Illumina had previously forecasted revenues of $625 to $630 million for the quarter, but citing “declining demand for its high-speed genetic sequences,” the Company only generated $607 million.

On this news, shares of Illumina were down as much as 25% during intraday trading on October 11, 2016.

If you purchased Illumina securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
20/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Illumina Inc.

Illumina, Inc.: Update to credit analysis

Our credit view of this issuer reflects its modest financial leverage, offset by US policies around research funding and tariffs.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Illumina, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 6 March 2026 in which we reassessed the appropriateness of the ratings in the context of the...

Illumina Inc: 1 director

A director at Illumina Inc sold 2,370 shares at 116.180USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Moody's Ratings assigns Baa3 rating to Illumina's senior notes; outloo...

Moody's Ratings (Moody's) assigned a Baa3 rating to the senior unsecured notes offering of Illumina, Inc. (Illumina). There are no changes to Illumina's existing ratings including the Baa3 senior unsecured notes, Baa3 issuer rating and (P)Baa3 senior unsecured shelf registration. The outlook is unch...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch